HAVN Life Sciences Inc. (HAVLF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | - | -7.87 Million | -10.42 Million | -75.01 Thousand |
| Net Income | - | -22.44 Million | -30.38 Million | -40.57 Thousand |
| Depreciation & Amortization | - | 575.62 Thousand | 4.6 Million | - |
| Deferred income taxes | - | 12.57 Million | - | - |
| Stock-based compensation | - | 1.78 Million | 9.13 Million | - |
| Change in working capital | - | -536.2 Thousand | -615.06 Thousand | -33.89 Thousand |
| Other non-cash items | - | 168.96 Thousand | 6.82 Million | -548.00 |
| Investing Cash Flow | - | -2.03 Million | -396.69 Thousand | -250 Thousand |
| Investments in PPE | - | -103.07 Thousand | -32.61 Thousand | - |
| Acquisitions | - | -1.2 Million | -346.05 Thousand | - |
| Investment purchases | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - |
| Other Investing Activities | - | -727.66 Thousand | -18.03 Thousand | -250 Thousand |
| Financing Cash Flow | - | 1.55 Million | 18.6 Million | 1.94 Million |
| Debt repayment | - | -130.94 Thousand | -32.73 Thousand | - |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | - | - | - | - |
| Common Stock Issuance | - | 1.99 Million | 14.13 Million | 1.92 Million |
| Other Financing Activities | - | -309.02 Thousand | 4.5 Million | 20 Thousand |
| Accounts receivables | - | -109.06 Thousand | -206.78 Thousand | - |
| Accounts payables | - | - | - | - |
| Inventory | - | - | - | - |
| Other working capital | - | -427.13 Thousand | -408.27 Thousand | -900.00 |
| Cash at beginning of period | 1.05 Million | 9.4 Million | 1.61 Million | -90.00 |
| Cash at end of period | 1.05 Million | 1.05 Million | 9.4 Million | 1.61 Million |
| Capital Expenditure | - | -103.07 Thousand | -32.61 Thousand | - |
| Effect of forex changes on cash | - | - | - | - |
| Net cash flow / Change in cash | - | -8.34 Million | 7.78 Million | 1.61 Million |
| Free Cash Flow | - | -7.97 Million | -10.45 Million | -75.01 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | - | - | - | -691.54 Thousand | 250.19 Thousand |
| Depreciation & Amortization | - | - | - | - | 105.00 | -23.47 Thousand |
| Deferred income taxes | - | - | - | - | 76.58 Thousand | 1.29 Million |
| Stock-based compensation | - | - | - | - | 59.69 Thousand | 276.25 Thousand |
| Change in working capital | - | - | - | - | 812.57 Thousand | 178.92 Thousand |
| Other non-cash items | - | - | - | - | 31.71 Thousand | -2.53 Million |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | -283.76 Thousand | 454.25 Thousand |
| Debt repayment | - | - | - | - | -283.76 Thousand | -32.73 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | 486.99 Thousand |
| Accounts receivables | - | - | - | - | 220.22 Thousand | -249.72 Thousand |
| Accounts payables | - | - | - | - | 573.18 Thousand | 194.87 Thousand |
| Inventory | - | - | - | - | -573.18 Thousand | -194.87 Thousand |
| Other working capital | - | - | - | - | 592.35 Thousand | 428.65 Thousand |
| Cash at beginning of period | - | - | 1.05 Million | 13.98 Thousand | 8631.00 | 112.41 Thousand |
| Cash at end of period | - | - | 1.05 Million | 13.98 Thousand | 13.98 Thousand | 8631.00 |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | - | - | 5355.00 | -103.78 Thousand |
| Free Cash Flow | - | - | - | - | 289.12 Thousand | -558.04 Thousand |
SHIP
MPH
ALGAU
HTJ
CHEMCON
8929